MX2022008013A - Estabilizacion de polipeptidos que contienen fragmentos cristalizables. - Google Patents

Estabilizacion de polipeptidos que contienen fragmentos cristalizables.

Info

Publication number
MX2022008013A
MX2022008013A MX2022008013A MX2022008013A MX2022008013A MX 2022008013 A MX2022008013 A MX 2022008013A MX 2022008013 A MX2022008013 A MX 2022008013A MX 2022008013 A MX2022008013 A MX 2022008013A MX 2022008013 A MX2022008013 A MX 2022008013A
Authority
MX
Mexico
Prior art keywords
polypeptides
stabilization
containing polypeptides
region
inteface
Prior art date
Application number
MX2022008013A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Frederick W Jacobsen
Jennifer Lavallee
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022008013A publication Critical patent/MX2022008013A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La descripción proporciona polipéptidos que comprenden una región Fc de anticuerpo que tiene una deleción de uno o más residuos de cisteína en la región de bisagra y sustitución con un residuo que contienen sulfhidrilo de uno o más aminoácidos de interfase CH3. También, se proporcionan proteínas de fusión Fc y anticuerpos que contienen los polipéptidos, ácidos nucleicos y vectores que codifican los polipéptidos, junto con células hospederas y métodos para elaborar los polipéptidos.
MX2022008013A 2013-07-31 2016-01-27 Estabilizacion de polipeptidos que contienen fragmentos cristalizables. MX2022008013A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31

Publications (1)

Publication Number Publication Date
MX2022008013A true MX2022008013A (es) 2022-07-27

Family

ID=52432568

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001165A MX2016001165A (es) 2013-07-31 2014-07-30 Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
MX2022008013A MX2022008013A (es) 2013-07-31 2016-01-27 Estabilizacion de polipeptidos que contienen fragmentos cristalizables.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016001165A MX2016001165A (es) 2013-07-31 2014-07-30 Estabilizacion de polipeptidos que contienen fragmentos cristalizables.

Country Status (15)

Country Link
US (2) US20160193295A1 (es)
EP (1) EP3027647A4 (es)
JP (2) JP2016526909A (es)
KR (2) KR20160034404A (es)
CN (1) CN105658664A (es)
AU (3) AU2014296215A1 (es)
BR (1) BR112016002219A2 (es)
CA (1) CA2919076C (es)
CL (1) CL2016000232A1 (es)
EA (1) EA035319B1 (es)
HK (1) HK1224203A1 (es)
IL (1) IL243690B (es)
MX (2) MX2016001165A (es)
SG (1) SG11201600734YA (es)
WO (1) WO2015017548A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
WO2016018931A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2015339130C1 (en) * 2014-10-31 2021-03-18 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2016100788A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
WO2017205014A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
CN116970060A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
EP3576789A4 (en) * 2017-02-01 2020-11-25 Centrymed Pharmaceuticals Inc. MONOMER HUMAN IGG1-FC AND BISPECIFIC ANTIBODIES
TWI832818B (zh) * 2017-07-07 2024-02-21 南韓商韓美藥品股份有限公司 新穎的治療性酵素融合蛋白及其用途
CA3071337A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
NZ765453A (en) * 2017-12-22 2024-03-22 Hanmi Pharmaceutical Co Ltd Therapeutic enzyme fusion protein having novel structure and use thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
MX2021001353A (es) 2018-08-03 2021-04-13 Amgen Res Munich Gmbh Constructos de anticuerpos para cldn18.2 y cd3.
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
WO2020243338A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
JP2022535060A (ja) 2019-06-07 2022-08-04 アムジエン・インコーポレーテツド 選択的に切断可能なリンカーを有する二重特異性結合構築物
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CN113372438A (zh) * 2020-02-25 2021-09-10 希森美康株式会社 改造抗体及其制造方法、以及提高抗体的热稳定性的方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
WO2022032660A1 (zh) * 2020-08-14 2022-02-17 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
KR20230097061A (ko) * 2020-11-02 2023-06-30 아트라러스, 인크. Sap fc 융합 단백질 및 사용 방법
BR112023008629A2 (pt) 2020-11-06 2023-10-03 Amgen Inc Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3
WO2022120286A1 (en) * 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN115925984A (zh) * 2021-08-24 2023-04-07 广东东阳光药业有限公司 Gdf15融合蛋白及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
AU751659B2 (en) * 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2007059782A1 (en) * 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP2013511281A (ja) * 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
WO2012078688A2 (en) 2010-12-06 2012-06-14 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer

Also Published As

Publication number Publication date
CA2919076C (en) 2024-01-30
HK1224203A1 (zh) 2017-08-18
JP7344858B2 (ja) 2023-09-14
EP3027647A4 (en) 2017-01-04
JP2016526909A (ja) 2016-09-08
JP2021019598A (ja) 2021-02-18
AU2020200329A1 (en) 2020-02-06
WO2015017548A3 (en) 2015-11-05
KR20160034404A (ko) 2016-03-29
US20190192628A1 (en) 2019-06-27
EP3027647A2 (en) 2016-06-08
KR20230141929A (ko) 2023-10-10
AU2014296215A1 (en) 2016-02-11
EA035319B1 (ru) 2020-05-27
CN105658664A (zh) 2016-06-08
IL243690B (en) 2022-09-01
SG11201600734YA (en) 2016-02-26
AU2022201204A1 (en) 2022-03-17
US20160193295A1 (en) 2016-07-07
BR112016002219A2 (pt) 2017-09-12
CA2919076A1 (en) 2015-02-05
CL2016000232A1 (es) 2016-09-02
IL243690A0 (en) 2016-04-21
EA201690299A1 (ru) 2016-11-30
WO2015017548A2 (en) 2015-02-05
MX2016001165A (es) 2016-06-29

Similar Documents

Publication Publication Date Title
MX2022008013A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
TN2015000085A1 (en) Fc containing polypeptides with altered glycosylation and reduced effector function
MX2018013738A (es) Anticuerpos que comprenden dominios constantes quimericos.
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
MX2022001134A (es) Proteinas quimericas de factor viii y usos de estas.
MX2019010846A (es) Polipeptidos de il-22 y proteinas de fusion de il-22 fc y metodos de uso.
MX2015011350A (es) Proteinas de fusion de apelina y usos de estas.
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
MX2018003445A (es) Expresion de proteinas que contienen fc.
WO2015015516A3 (en) Expression vector for production of recombinant proteins in prokaryotic host cells
NZ750009A (en) Antibodies comprising chimeric constant domains